-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020.
Docetaxel injection has more than 20 manufacturers.
Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020.
Docetaxel injection has more than 20 manufacturers.
Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
Statistics show that docetaxel is paclitaxel class of anti- cancer drugs, by interfering with the cells between mitosis and cell division of functions necessary microtubule network sky antitumor effect.
Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
Sales of terminal docetaxel injections in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Meinenet, in 2019, the sales of terminal docetaxel injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 4 billion yuan, a year-on-year decrease of 12.
71% in 2020.
.
There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
Rear.
71% in 2020.
.
There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
Rear.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, docetaxel injection has been reviewed by 6 companies .
Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
Once approved, it is deemed to have been reviewed.
Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
Once approved, it is deemed to have been reviewed.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020.
Docetaxel injection has more than 20 manufacturers.
Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020.
Docetaxel injection has more than 20 manufacturers.
Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
Statistics show that docetaxel is paclitaxel class of anti- cancer drugs, by interfering with the cells between mitosis and cell division of functions necessary microtubule network sky antitumor effect.
Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
Sales of terminal docetaxel injections in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Meinenet, in 2019, the sales of terminal docetaxel injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 4 billion yuan, a year-on-year decrease of 12.
71% in 2020.
.
There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
Rear.
71% in 2020.
.
There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
Rear.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, docetaxel injection has been reviewed by 6 companies .
Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
Once approved, it is deemed to have been reviewed.
Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
Once approved, it is deemed to have been reviewed.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News, May 8 Recently, the official website of the State Food and Drug Administration showed that the docetaxel injection of Sichuan Meida Kangjiale Pharmaceutical was approved as a supplementary application.
According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020.
Docetaxel injection has more than 20 manufacturers.
Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
According to data from Meinenet, the sales of terminal docetaxel injections in China's public medical institutions exceeded 4 billion yuan in 2019, a year-on-year decrease of 12.
71% in 2020.
Docetaxel injection has more than 20 manufacturers.
Among them, Jiangsu Hengrui Medicine has the largest market share, followed by Sanofi.
Statistics show that docetaxel is paclitaxel class of anti- cancer drugs, by interfering with the cells between mitosis and cell division of functions necessary microtubule network sky antitumor effect.
Docetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
Tumor tumor tumorDocetaxel injection was first developed and produced by the French Rhone Planck Lean Company (now Sanofi-Aventis).
Sales of terminal docetaxel injections in public medical institutions in China in recent years
Source: Terminal competition landscape of China's public medical institutions
According to data from Meinenet, in 2019, the sales of terminal docetaxel injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 4 billion yuan, a year-on-year decrease of 12.
71% in 2020.
.
There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
Rear.
Hospital Hospital Hospital Medicine Medicine Medicine71% in 2020.
.
There are more than 20 manufacturers of docetaxel injection, including Jiangsu Hengrui Pharmaceutical , Sanofi, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Jiangsu Osaikang, etc.
Among them, Jiangsu Hengrui Pharmaceutical has the largest market share, and Sanofi follows closely.
Rear.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, docetaxel injection has been reviewed by 6 companies .
Among them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
Once approved, it is deemed to have been reviewed.
Enterprise business enterpriseAmong them, Sichuan Huiyu Pharmaceutical has been approved for production of generic 4 types, which is deemed to have been reviewed; Jiangsu Hengrui Pharmaceutical and Zhengda Tianqing Pharmaceutical The Group, Qilu Pharmaceutical, Yangtze River Pharmaceutical Group, and Sichuan Meida Kangjiale Pharmaceutical have all been approved as supplementary applications.
In addition, supplementary applications for consistency evaluation of three companies including Jiangsu Aosaikang Pharmaceutical and Shanghai Chuangnuo Pharmaceutical are under review and approval.
Yangzijiang Pharmaceutical Group and Luoxin Biotechnology have submitted their application for listing in 4 categories of imitations and are under review and approval.
Once approved, it is deemed to have been reviewed.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
